Phase 3 N=50 A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
Postoperative Pain · Postoperative Nausea and Vomiting
Primary: Prevalence of Postoperative Gut Dysfunction — 13; 15 Participants — p=0.264
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=798 Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children
Whole Cell Pertussis · Tetanus · Hepatitis B
Primary: Number of Subjects With Fever >39°C (Rectal Route). — 22; 8; 5; 3 Participants
Phase 3 N=300 A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
ADHD · Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
Primary: Change in Total ADHD Symptom Score With Adult Prompts of the Conners Adult ADHD Rating Scale:O-SV in ADHD Adults From Baseline to 6 Weeks — -9.9; -12.0 Change in Score…
Phase 3 N=2,103 Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 — 0.126; 0.066; 0.062; 0.105 Liters
Phase 3 N=1,615 Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Morning Pre-dose Trough FEV1 — 0.061; 0.063; 0.116; 0.013 Liters
Phase 3 N=24 Pharmacologic Treatment of PTSD in Sexually Abused Children
Stress Disorders, Post-Traumatic
Primary: Kiddie-Sads-Present and Lifetime (KSADS-PL) Scale for PTSD — 8; 6; 1; 5 Participants
Phase 3 N=515 Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase — 9.6; 75.3 percentage of participants — p=< 0.001
Phase 3 N=239 Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
Schizophrenia
Primary: Percentage of Participants With Adverse Events (AEs) — 60.2; 56.4; 65.2; 60.5 percentage of participants
Phase 3 N=891 Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events (AEs) — 354; 337; 108; 799 participants
Phase 3 N=531 Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
Chronic Stable Plaque Psoriasis
Primary: PASI 75 Response Rate at Week 12 - GP2015 Etanercept vs. Enbrel ® Etanercept — 73.4; 75.7 % of patients achieving PASI75 response
Phase 3 N=242 Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: HbA1c (Glycosylated Haemoglobin) for Participants Treated With PDS290 and FlexPen® — 7.5; 7.5 percentage (%) of total haemoglobin
Phase 3 N=80 Gastroesophageal Reflux Treatment in Scleroderma
Gastroesophageal Reflux Disease · Systemic Sclerosis · Scleroderma
Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)
Phase 3 N=636 Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
Multiple Sclerosis
Primary: Proportion of Participants Achieving a Mean Improvement of ≥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 Weeks — 0.336; 0.432…
Phase 3 N=508 Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase — 8.3; 74.0 percentage of participants — p=<0.001
Phase 3 N=701 Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant…